Cardiac Stem Cell Isolation via ALDH Activity and Hoechst Efflux
Solution Overview
Problem
Current methods for isolating cardiac stem cells from heart tissue are inefficient due to non-specific binding and heterogeneity, often resulting in populations that include mobilized bone marrow cells and lack the ability to differentiate into functional cardiomyocytes.
Innovation Solution
A novel population of cardiac stem cells, referred to as CASCs, is isolated based on high aldehyde dehydrogenase activity and specific surface marker expression (ALDH+, CD34+, CD45-), which can differentiate into functional cardiomyocytes and maintain this ability upon expansion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If magnetic bead sorting based on antigen-antibody interaction is used to isolate cardiac stem cells, then isolation efficiency is improved, but the population becomes heterogeneous due to non-specific binding
Solution Approach 1:
The patent uses Hoechst 33342 dye as an intermediary substance to identify and isolate cardiac stem cells. The dye accumulates in cells with active ABC transporters (a characteristic of CSCs), and its efflux properties serve as a biological mediator to distinguish CSCs from other cell types, avoiding the non-specific binding issues of antibody-based methods
Solution Approach 2:
The patent changes the isolation parameter from surface antigen expression (which leads to heterogeneous populations) to intracellular dye efflux capability (which provides homogeneous CSC isolation). By measuring the efflux rate of Hoechst 33342, the method identifies CSCs based on their functional characteristic of active ABC transporter expression
2Ease of manufacture
If surface markers like Sca-1 or c-kit are used for isolation, then the isolation process is simplified, but the population includes non-cardiac stem cells from bone marrow
Solution Approach 1:
The patent employs Hoechst 33342 dye efflux as a biological intermediary to distinguish cardiac stem cells from bone marrow-derived cells. Since ABC transporter activity is specific to CSCs and not present in mobilized bone marrow cells, this intermediary provides a functional basis for pure CSC isolation
Solution Approach 2:
The patent replaces the mechanical/chemical system of antibody-antigen binding with a biological functional assay based on dye efflux. This substitution eliminates the cross-reactivity and non-specific binding problems inherent in antibody-based methods while maintaining isolation effectiveness
3Adaptability or versatility
If Hoechst 33342 or Rhodamine 123 efflux is used for isolation, then functional stem cell properties are utilized, but the isolated population becomes very heterogeneous
Solution Approach 1:
The patent refines the dye efflux parameter by selecting Hoechst 33342 at specific concentrations and measuring efflux under controlled conditions. By optimizing these parameters, the method achieves both functional-based isolation and population homogeneity, distinguishing CSCs from other cell types more precisely than previous dye efflux methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CASCs provide a homogeneous population capable of differentiating into functional cardiomyocytes, offering therapeutic potential for heart repair and tissue regeneration.
Implementation Method 1
These cells are able to differentiate in to functional cardiomyocytes as shown by RT-PCR, immunofluorescence, TEM and electrophysiological measurements. The novel cardiac stem cells of the invention express high levels of ALDH activity (ALDH+)
Data Source
Figure 1aa~1n
Figure 2aa~2g
Figure 3
AI summary
The invention relates to a novel population of cardiac stem cells which are positive for aldehyde dehydrogenase activity, express CD34, and do not express c-kit or CD45. These cells are different from previously identified cardiac stem cells, mesenchymal stem cells or HSCs. The invention provides methods for isolating these cells and the use of these cells and expanded cell populations thereof for use in heart repair.